
Lung Transplant Program
On this page
Get care
Why choose UCSF Health for lung transplant?
Since 1991, we've given more than 1,000 people with advanced lung disease a new chance at life. UCSF Health performs more lung transplants than any other center on the West Coast, and our outcomes far exceed national averages.
We welcome challenging and high-risk cases. Our advanced approach enables us to accept more high-risk patients for transplant. We also offer reevaluations and second opinions for cases that may have been turned down elsewhere.
You receive comprehensive care before transplant, so you are ready when a lung or lungs become available. Your transplant team guides you through the entire process, from evaluation to the waitlist to transplantation and life after surgery.
Why choose UCSF Health for lung transplant?
Since 1991, we've given more than 1,000 people with advanced lung disease a new chance at life. UCSF Health performs more lung transplants than any other center on the West Coast, and our outcomes far exceed national averages.
We welcome challenging and high-risk cases. Our advanced approach enables us to accept more high-risk patients for transplant. We also offer reevaluations and second opinions for cases that may have been turned down elsewhere.
You receive comprehensive care before transplant, so you are ready when a lung or lungs become available. Your transplant team guides you through the entire process, from evaluation to the waitlist to transplantation and life after surgery.
Get care
Outstanding outcomes
Our one- and three-year survival rates are among the best in the nation, far above the national averages.More available donor lungs
Our transplant innovations create a larger pool of available donor lungs, shortening waitlist times for our patients.Multi-organ transplant expertise
We're one of the few centers in the nation performing multi-organ transplants, such as heart-lung, lung-kidney and lung-liver.Lifelong partnership
We're committed to your long-term well-being, continuing to monitor your health and support you for life.
Lung transplant support and care
UCSF Health lung transplant providers have worked together for many years, enabling us to provide seamless, comprehensive, whole-person care. Your transplant team includes:
Surgeon
Pulmonologist
Nurse coordinator
Anesthesiologist
Nutritionist
Pharmacist
Respiratory therapist
Physical therapist
Psychiatrist
Social worker
Case manager
We guide you through every step of the transplant process, coordinating your care from evaluation to surgery to life after transplant. Your dedicated team continues to support you at follow-up appointments. Between appointments, we are available to answer questions and provide help.
Supporting you through the lung transplant journey
We understand the challenges of waiting for donor lungs. We keep your condition stable, so you are ready for transplant when a lung becomes available. Our specialists treat a range of lung conditions, including:
Alpha-1 antitrypsin deficiency
Bronchiectasis
Chronic obstructive pulmonary disease
After transplant, you'll need to stay nearby so we can support you and monitor your recovery. The Kôz Hospitality House provides comfortable, affordable private rooms and communal kitchens for transplant recipients and their caregivers.
Once you return home, we continue to monitor you closely. We have outreach clinics to bring lung transplant care close to home and use telehealth appointments in between visits. We also monitor your condition remotely, using personal spirometry devices that collect information on your lung function. This monitoring helps us identify early signs of organ rejection so we can intervene with treatment.
We also offer a network of people and resources for you and your loved ones. You and your caregivers are welcome at our free transplant support group meetings before and after transplant.
Making more donor lungs available
We are leading efforts to safely expand the pool of available donor lungs, reducing time on the waitlist. Our team has:
Expanded the number of lungs available from hepatitis C-positive donors
Used temperature-controlled devices for transporting donor lungs, enabling the team to travel over longer distances
Increased the number of viable donor lungs available after circulatory death
Used ex vivo lung perfusion technology to recondition donor lungs
Locations
Providers

Jasleen Kukreja, MD
Lung Transplant Surgery • Cardiothoracic Surgery
Tobias Deuse, MD
Lung Transplant Surgery • Cardiothoracic Surgery
Steven Hays, MD
Lung Transplant Surgery • Chronic Obstructive Pulmonary Disease
Jeffrey A. Golden, MD
Chronic Obstructive Pulmonary Disease • Interstitial Lung Disease
Recognition for lung transplant excellence

Best in the West and No. 3 in the nation for pulmonology & lung surgery

Top-performing lung transplant program
#1
in the U.S. for patient survival rates three years after lung transplant
Related conditions & treatments
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Cystic Fibrosis
- Chronic Obstructive Pulmonary Disease
- Pulmonary Hypertension
Treatments
Clinical trials
4D-710 in Adult Patients With Cystic FibrosisOpens in a new window
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.Exercise-based Frailty Intervention in Lung Transplantation (XFIT)Opens in a new window
The goal of XFIT study is to measure the safety of an 8-week telehealth-delivered exercise and behavioral training program to treat frailty in lung transplant candidates in their own home. The main questions XFIT aims to answer are: Is XFIT safe? Is XFIT feasible and acceptable by participants? Is XFIT effective in improving frailty and physical function as reflected in patient-reported outcomes.This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft DysfunctionOpens in a new window
Lung transplant recipient survival lags other solid organ recipients, with the main early cause of death being primary graft dysfunction (PGD). PGD occurs in up to 1/3 of all recipients, is driven by the body's innate immune response, and has no known medical therapies for treatment or prevention. Investigators have recently shown that Natural Killer (NK) cells, a key innate immune cell, are critical in causing PGD. Importantly, the investigators found that Maraviroc, an FDA-approved drug that works to inhibit these immune cells, prevented lung injury in mouse models of PGD.10°C vs 4°C Lung Preservation RCTOpens in a new window
PGD is graded on a scale of 0 to 3 based on ISHLT guidelines, where PGD Grade 3 indicates severe primary graft dysfunction.Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)Opens in a new window
To demonstrate a reduction in lung function decline for ifetroban compared to placebo over 52 weeks.
Empowerment through education
Patient Stories
1 of 2







